ARQ-234
Atopic Dermatitis
Preclinical/Phase 1Investigational
Key Facts
Indication
Atopic Dermatitis
Phase
Preclinical/Phase 1
Status
Investigational
Company
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, founded in 2016, is a public biotech company dedicated to meaningful innovation in medical dermatology. It leverages a proprietary topical formulation platform to develop targeted therapies, primarily PDE4 inhibitors, for chronic inflammatory skin conditions. The company has secured six FDA approvals for its ZORYVE franchise and is advancing a diverse pipeline, including a biologic candidate for atopic dermatitis, to address significant unmet patient needs.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Phase 3 |
| Dupixent | Sanofi | Commercial |
| ASP2408 | Astellas Pharma | Phase 2 |
| KW-6356 | Kyowa Kirin | Phase 2 |
| KHK4083 | Kyowa Kirin | Phase 2 |
| Opzelura (ruxolitinib cream) | Ono Pharmaceutical | Approved |
| ONO-7913 | Ono Pharmaceutical | Phase 2 |
| KT-474 | Kymera Therapeutics | Phase 2 |
| GRC 27864 | Glenmark Pharmaceuticals | Phase 2 |
| STAR-0310 | BioCryst Pharmaceuticals | Phase 1 |
| Rezpegaldesleukin | Nektar Therapeutics | Phase 2b |
| ZL-1503 | Zai Lab | Phase (Early Clinical) |